Cryptex Finance Appoints Canary Capital as Strategic Advisor
Canary Capital will advise Cryptex Finance on market structure, index construction, and institutional execution as the protocol transitions to production-grade financial infrastructure. The engagement reflects increasing institutional alignment around transparent, rules-based exposure to the digital asset market.
Since its founding in 2021, Cryptex Finance has focused on a singular objective: building durable digital asset indexes capable of operating across both on-chain and traditional financial systems. The protocol has facilitated billions of dollars in governance activity while maintaining a decentralization-first design for its indexes.
"Canary understands where digital asset markets are heading and what it takes to build products that institutions can actually deploy capital into," said
The relationship comes as Cryptex Finance moves toward
Canary Capital brings experience managing approximately
Further updates will be announced as Cryptex Finance reaches additional milestones.
About Cryptex Finance
Cryptex Finance is a decentralized protocol building digital asset index infrastructure designed for long-term, institutional-grade market access across both on-chain and traditional financial systems.
About Canary Capital
Canary Capital offers Institutional crypto asset trading and management via discretionary risk-managed crypto hedge fund and single-asset trusts.
Disclaimer
This announcement is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities or financial instruments. Forward-looking statements reflect current expectations and are subject to risks and uncertainties that may cause actual outcomes to differ materially.
View original content:https://www.prnewswire.com/news-releases/cryptex-finance-appoints-canary-capital-as-strategic-advisor-302660057.html
SOURCE Cryptex Finance
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
- Immune Thrombocytopenic Purpura (ITP) Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2025-2034 | DelveInsight
- It’s Not Too Late: Zeagoo Celebrates 13 Years of Empowering Women’s Style with Maye Musk
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Hedge FundsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share